Fate Therapeutics, Inc. (FATE)
1.05
-0.02
(-1.87%)
USD |
NASDAQ |
Dec 09, 16:00
1.05
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics EPS Diluted (Quarterly): -0.271 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| NovaBay Pharmaceuticals, Inc. | -0.22 |
| Palatin Technologies, Inc. | 4.258 |
| Theriva Biologics, Inc. | -0.4507 |
| Oragenics, Inc. | -1.965 |
| NanoViricides, Inc. | -0.1045 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.25M |
| Revenue (Quarterly) | 1.741M |
| Total Expenses (Quarterly) | 33.99M |
| Enterprise Value | -15.06M |
| Gross Profit Margin (Quarterly) | -85.35% |
| Profit Margin (Quarterly) | -1.85K% |
| Earnings Yield | -125.6% |
| Normalized Earnings Yield | -117.73 |